Literature DB >> 11558564

Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells.

N Iida1, K Takara, N Ohmoto, T Nakamura, T Kimura, A Wada, M Hirai, T Sakaeda, K Okumura.   

Abstract

In this study, the antiproliferative effects of vinblastine (VLB), paclitaxel (TXL), doxorubicin (DXR), daunorubicin (DNR) and 5-fluorouracil (5-FU) were assessed in the human cervical carcinoma cell line HeLa-Ohio (HeLa) and Hvr100-6 cells, established by growing the parental HeLa cells in the presence of progressively greater concentrations of VLB in the culture medium. Flow cytometric analysis indicated the induction of MDR1 (P-glycoprotein) in Hvr100-6 cells with no alterations in levels of multidrug resistance-associated protein (MRP). Resistance to VLB, TXL, DXR and DNR was found in Hvr100-6 cells with relative resistances of ca. 300, 4000, 50 and 200, respectively, whereas no resistance was found to 5-FU. The reversal effects of antifungal drugs, fluconazole, itraconazole, ketoconazole, miconazole and amphotericin B on multidrug resistance were also assessed using Hvr100-6 cells. Itraconazole was found to have potent reversal effect on the resistance to VLB and TXL, but the others had no such effect. This reversal effect of itraconazole was concentration-dependent, with dose modifying factors of 3.2, 10.1 and 435.7 at 0.1, 0.25 and 0.5 microM of itraconazole, respectively. In addition, this reversal effect of itraconazole was explained by the inhibition of accumulation of the anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558564     DOI: 10.1248/bpb.24.1032

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

1.  MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling.

Authors:  Toshiyuki Sakaeda; Tsutomu Nakamura; Midori Hirai; Takashi Kimura; Atsushi Wada; Tatsurou Yagami; Hironao Kobayashi; Shunji Nagata; Noboru Okamura; Takayoshi Yoshikawa; Toshiro Shirakawa; Akinobu Gotoh; Masafumi Matsuo; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 2.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

3.  In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier.

Authors:  Ji-Qin Wu; Kun Shao; Xuan Wang; Rui-Ying Wang; Ya-Hui Cao; Yun-Qiu Yu; Jin-Ning Lou; Yan-Qiong Chen; Hua-Zhen Zhao; Qiang-Qiang Zhang; Xin-Hua Weng; Chen Jiang; Li-Ping Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.

Authors:  Nisana Tepsiri; Liengchai Chaturat; Banchob Sripa; Wises Namwat; Sopit Wongkham; Vajarabhongsa Bhudhisawasdi; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

5.  Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Authors:  Jing Jin; Min Huang; Huai-Ling Wei; Geng-Tao Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  Pattern-based sensing of triple negative breast cancer cells with dual-ligand cofunctionalized gold nanoclusters.

Authors:  Yu Tao; Mingqiang Li; Debra T Auguste
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

7.  Co-delivery of doxorubicin and itraconazole by Pluronic® P123 coated liposomes to enhance the anticancer effect in breast cancers.

Authors:  Yi Lin; Xiaodan He; Dinglun Zhou; Li Li; Jiawei Sun; Xuehua Jiang
Journal:  RSC Adv       Date:  2018-06-29       Impact factor: 4.036

Review 8.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Induced Cell Cycle Arrest in Triple-Negative Breast Cancer by Combined Treatment of Itraconazole and Rapamycin.

Authors:  Hua-Tao Wu; Chun-Lan Li; Ze-Xuan Fang; Wen-Jia Chen; Wen-Ting Lin; Jing Liu
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

10.  Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Lydie Meheus; Vidula Sukhatme; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2014-07-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.